Every material Form 8-K RxSight, Inc. has filed with the SEC since July 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
RxSight reported third quarter 2026 results for the period ended September 30, 2026, with total revenue down 19% from the prior-year quarter, primarily reflecting ongoing competitive pressures. The net loss widened to $16.2 million, or $0.39 per share, from $9.8 million, or $0.24 per share, a year earlier, and gross margin fell to 73.6% from 79.9%. Shareholders also get a company that ended the quarter with $254.7 million in cash and short-term investments, including $60 million received in connection with the Alcon collaboration.
Third quarter total revenue was $24.6 million, down 19% from $30.3 million a year earlier; the filing cites ongoing competitive pressures.
Net loss was $16.2 million, or $0.39 per share, versus $9.8 million, or $0.24 per share, in the third quarter of 2025.
Gross margin was 73.6%, compared with 79.9%, reflecting higher inventory reserves and higher inventory costs.
Cash, cash equivalents and short-term investments totaled $254.7 million as of September 30, 2026; the company also appointed Taryn Conway as Chief Commercial Officer.
RxSight reported second-quarter 2026 total revenue of $33.7 million, roughly flat with the prior year, but product sales fell 19% to $27.2 million, and the net loss was $12.1 million, or $0.29 per share. The company withdrew its 2026 guidance in connection with the appointment of new President and CEO Aziz Mottiwala, and said it will resume formal guidance in early 2027.
Total revenue was $33.7 million, including $6.5 million from the Alcon collaboration; product sales were $27.2 million versus $33.6 million in the prior-year quarter.
Gross margin excluding the Alcon collaboration was 71.2%, down from 74.9%, which the company attributed to inventory-related costs.
Net loss was $12.1 million ($0.29 per share), compared with $11.8 million ($0.29 per share) a year earlier; adjusted net loss was $4.6 million ($0.11 per share) versus $3.3 million ($0.08).
2026 guidance was withdrawn; cash, cash equivalents and short-term investments totaled $208.8 million as of June 30, 2026.
RxSight's board appointed Aziz Mottiwala as President and Chief Executive Officer on July 13, 2026, effective July 20, 2026, replacing Ron Kurtz, M.D., who has led the company since 2016. Kurtz moves to Chief Medical Officer and resigns from the board, and Mottiwala joins the board in his place. The company said it is not updating its previously communicated financial guidance.
Mottiwala, 48, was Chief Commercial Officer of Tarsus Pharmaceuticals from August 2020 to July 2026.
Mottiwala's pay includes a $750,000 base salary, a 2026 cash bonus of $337,500, and equity awards with a grant-date value of $14,000,000.
Kurtz keeps a $740,000 base salary and can earn retention bonuses of $370,000 on each of four dates from January 1, 2027 through July 1, 2028, if he remains employed.
The company is not updating its previously communicated financial guidance in connection with the announcement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RxSight, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →